Όλο το DSpace

Πλοήγηση ανά Θέμα "procalcitonin"

Αποτελέσματα 1-9 από 9

    • Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19 

      Pan M., Vasbinder A., Anderson E., Catalan T., Shadid H.R., Berlin H., Padalia K., O’hayer P., Meloche C., Azam T.U., Khaleel I., Michaud E., Blakely P., Bitar A., Huang Y., Zhao L., Pop-Busui R., Loosen S.H., Chalkias A., Tacke F., Giamarellos-Bourboulis E.J., Reiser J., Eugen-Olsen J., Hayek S.S. (2021)
      BACKGROUND: Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARB) is thought to affect COVID-19 through modulating levels of angiotensin-converting enzyme 2, the cell entry receptor ...

    • Baseline Values and Kinetics of IL-6, Procalcitonin, and TNF- α in Landrace-Large White Swine Anesthetized with Propofol-Based Total Intravenous Anesthesia 

      Chalkias A., Spyropoulos V., Georgiou G., Laou E., Koutsovasilis A., Pantazopoulos I., Kolonia K., Vrakas S., Papalois A., Demeridou S., Gourgoulianis K., Dontas I., Kaparos G., Baka S., Xanthos T. (2021)
      The baseline levels of various inflammatory mediators and their changes during anesthesia in swine are not known. The aim of this animal study was to measure the baseline values and kinetics of interleukin-6, procalcitonin, ...

    • Characteristics and outcomes of cancer patients who develop pulmonary embolism: A cross-sectional study 

      Chlapoutakis S., Georgakopoulou V.E., Trakas N., Kouvelos G., Papalexis P., Damaskos C., Sklapani P., Grivas A., Gouveris P., Tryfonopoulos D., Tzovaras A., Ardavanis-Loukeris G., Grouzi E., Spandidos D.A., Matsagkas M. (2021)
      Pulmonary embolism (PE), along with deep vein thrombosis, are collectively known as venous thromboembo- lism (VTE). Predisposing factors for PE include post-operative conditions, pregnancy, cancer and an advanced age; of ...

    • Circulating suPAR associates with severity and in-hospital progression of COVID-19 

      Chalkias A., Skoulakis A., Papagiannakis N., Laou E., Tourlakopoulos K., Pagonis A., Michou A., Ntalarizou N., Mermiri M., Ragias D., Bernal-Morell E., Cebreiros López I., García de Guadiana-Romualdo L., Eugen-Olsen J., Gourgoulianis K., Pantazopoulos I., Chalkias A., Skoulakis A., Laou E., Michou A., Ntalarizou N., Mermiri M., Ragias D., Tourlakopoulos K., Pagonis A., Gourgoulianis K., Pantazopoulos I., Papagiannakis N., Kampolis C., García de Guadiana-Romualdo L., Albaladejo-Otón M.D., Rodríguez Mulero M.D., Galindo Martínez M., Hernández Olivo M., Campos Rodríguez V., Cebreiros López I., Arnaldos Carrillo M., Noguera Velasco J.A., Pascual Figal D.A., Bernal-Morell E., Alcaraz García A., Alcaraz García M.J., Martínez Martínez M., Esteban-Torrella P., Sancho-Rodríguez N., Eugen-Olsen J., for the SPARCOL Investigators (2022)
      Background: COVID-19 disease progression is characterized by hyperinflammation and risk stratification may aid in early aggressive treatment and advanced planning. The aim of this study was to assess whether suPAR and other ...

    • Clozapine associated with autoimmune reaction, fever and low level cardiotoxicity - a case report 

      Gerasimou C., Vitali G.P., Vavougios G.D., Papageorgiou C., Douzenis A., Kokoris S.I., Liappas I., Rizos E. (2017)
      Background: Clozapine is a second-generation antipsychotic drug used in treatment-resistant schizophrenia. Fever induced by clozapine is a rather frequent side-effect which usually occurs in the first 4 weeks of treatment. ...

    • Early bacterial identification among intubated patients with COVID-19 or influenza pneumonia: A european multicenter comparative clinical trial 

      Rouzé A., Martin-Loeches I., Povoa P., Metzelard M., Cheyron D.D., Lambiotte F., Tamion F., Labruyere M., Geronimi C.B., Nieszkowska A., Nyunga M., Pouly O., Thille A.W., Megarbane B., Saade A., Diaz E., Magira E., Llitjos J.-F., Cilloniz C., Ioannidou I., Pierre A., Reignier J., Garot D., Kreitmann L., Baudel J.-L., Fartoukh M., Plantefeve G., Beurton A., Asfar P., Boyer A., Mekontso-Dessap A., Makris D., Vinsonneau C., Floch P.-E., Weiss N., Ceccato A., Artigas A., Bouchereau M., Duhamel A., Labreuche J., Nseir S., Poissy J., Favory R., Preau S., Jourdain M., Boyd S., Coelho L., Maizel J., Cuchet P., Zarrougui W., Boyer D., Quenot J.-P., Imouloudene M., Luyt C.-E., van der Linden T., Bardin J., Voicu S., Azoulay E., Goma G., Pene F., Torres A., Thevenin D., Ehrmann S., Argaud L., Guidet B., Voiriot G., Contou D., Le Marec J., Demiselle J., Meguerditchian D., Razazi K., Tsolaki V., Sejourne C., Brunin G., LeGuennec L., Morales L., the coVAPid Study Group (2021)
      Rationale: Early empirical antimicrobial treatment is frequently prescribed to critically ill patients with coronavirus disease (COVID-19) based on Surviving Sepsis Campaign guidelines. Objectives: We aimed to determine ...

    • Incorporating Biomarkers in COPD Management: The Research Keeps Going 

      Pantazopoulos I., Magounaki K., Kotsiou O., Rouka E., Perlikos F., Kakavas S., Gourgoulianis K. (2022)
      Globally, chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality, having a significant socioeconomic effect. Several molecular mechanisms have been related to COPD including chronic ...

    • Initial Immune Response in Escherichia coli, Staphylococcus aureus, and Candida albicans Bacteremia 

      Spyropoulos V., Chalkias A., Georgiou G., Papalois A., Kouskouni E., Baka S., Xanthos T. (2020)
      Sepsis remains a leading cause of mortality worldwide and is characterized by sustained inflammatory responses, reflected as changes in the expression profile of cytokines with time. The aim of the present study was to ...

    • Management of covid-19 patients in the emergency department 

      Pantazopoulos I., Tsikrika S., Kolokytha S., Manos E., Porpodis K. (2021)
      COVID-19 is an emerging disease of global public health concern. As the pandemic overwhelmed emergency departments (EDs), a restructuring of emergency care delivery became necessary in many hospitals. Furthermore, with ...